Interpretation of results of pooled analysis of individual patient data by Freemantle, N & Pagano, D
Dear Sir / Madam 
Conclusions methodologically unsound and risks unnecessary and avoidable deaths in patients 
The recent collaborative individual patient meta analysis on PCI versus CABG by Head et al (2018)[1] 
is a very welcome addition to the literature, establishing convincingly the superiority of CABG over 
PCI on the important outcome of all cause mortality (HR 1·20, 95% CI 1·06–1·37; p=0·004).  However 
the conclusions offered by the authors are methodologically incorrect and their publication in a 
major journal surprising.[2] 
The challenges of subgroup analyses are well known including to readers of this journal [3,4,5] and 
must be established on the basis of both prespecified biological plausibility and statistical rigour.  
Accounting for multiplicity, none of the tests for interaction undertaken by the authors are 
statistically significant.  Thus the correct interpretation is that the main effect (benefit for CABG over 
PCI) should be applied to all subgroups including patients with left main disease.  The suggestion in 
the paper by Head et al (2018) that the lack of benefit found in many subgroups supports a 
conclusion differing from this is methodologically unsound and risk unnecessary and avoidable 
deaths in patients.  These points should be corrected. 
Nick Freemantle PhD, Institute of Clinical Trials and Methodology, University College London, Gower 
Street, London UK 
Domenico Pagano, Quality and Outcomes Research Unit, University Hospitals Birmingham NHS 
Foundation Trust, Birmingham, UK. 
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